Revised Mayo Clinic AL Amyloidosis Staging System Staging system for newly-diagnosed light-chain amyloidosis, incorporating serum free light chains Value Points 1. Sum the number of risk factors Difference between serum free kappa and lambda light chains (mg/L) Difference between serum free kappa and lambda light chains: < 180 mg/L 180 mg/L or higher Troponin T (cTNT), ng/L Troponin T (cTNT): < 25 ng/L 25 ng/L or higher NT-proBNP, ng/L NT-proBNP: < 1800 ng/L (< 213 pmol/L) 1800 ng/L (213 pmol/L) or higher 2. Determine prognostic stage Number of risk factors: Risk factors Revised Prognostic Stage Median OS (months)1 Five-year survival1 Sum of score 0 I 94 59% Risk category 1 II 40 42% 2 III 14 20% 3 IV 6 14% Reference Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012 Mar 20;30(9):989-95. doi: 10.1200/JCO.2011.38.5724. Epub 2012 Feb 13.